The authors employed multiple functional analyses to characterize the role of Zinc Finger Protein 207 (ZFP207) in mouse ESCs.
[EMBO Reports]
[zotpress userid=’7992332′ items=’EEEEEEEE’ style=’apa’ cite=’yes’]
Category Archives: ESC & iPSC
ESC & iPSC NewsESC & iPSC News is an online publication and email newsletter dedicated to the latest research in the fields of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).
Since 2007, ESC & iPSC News has been providing weekly updates on the top publications, reviews, and news in pluripotent stem cell research. Through our website, Twitter, and email newsletters, our editorial team is proud to help keep researchers and medical professionals up-to-date with the latest discoveries, jobs, and event postings in the pluripotent stem cell field.
ZFP207 Sustains Pluripotency by Coordinating OCT4 Stability, Alternative Splicing and RNA Export
Japan University Uses iPS Cells to Treat Spinal Cord Injury for First Time
Keio University in Tokyo said it has started the world’s first clinical test using induced pluripotent stem cells, or iPS cells, to treat patients with spinal cord injuries.
[Kyodo News]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Establishment of a Developmental Toxicity Assay Based on Human iPSC Reporter to Detect Fibroblast Growth Factor Signal Disruption
Scientists proposed a reporter assay that utilized human iPSCs to detect changes in fibroblast growth factor signaling, which was essential for limb morphogenesis.
[iScience]
[zotpress userid=’7992332′ items=’EEEEEEEE’ style=’apa’ cite=’yes’]
Recapitulating Human Cardio-Pulmonary Co-development Using Simultaneous Multilineage Differentiation of Pluripotent Stem Cells
The authors reported a novel stepwise strategy for directing the simultaneous induction of both mesoderm-derived cardiac and endoderm-derived lung epithelial lineages within a single differentiation of human iPSCs via temporal specific tuning of WNT and nodal signaling in the absence of exogenous growth factors.
[eLife]
[zotpress userid=’7992332′ items=’EEEEEEEE’ style=’apa’ cite=’yes’]
Single-Cell Transcriptomics of Human iPSC Differentiation Dynamics Reveal a Core Molecular Network of Parkinson’s Disease
Researchers investigated Parkinson’s disease (PD)’s mechanism using dopaminergic neurons differentiated from human iPSCs carrying the ILE368ASN mutation within the PINK1 gene, which is strongly associated with PD.
[Communications Biology]
[zotpress userid=’7992332′ items=’EEEEEEEE’ style=’apa’ cite=’yes’]
Integrated Stem Cells from Apical Papilla in a 3D Culture System Improve Human Embryonic Stem Cell Derived Retinal Organoid Formation
The authors assessed the effective interactions of mesenchymal stem cells and human embryonic stem cells during retinal organoid formation.
[Life Sciences]
[zotpress userid=” items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Memorial Sloan Kettering Cancer Center Announces the Creation of the Fiona and Stanley Druckenmiller Presidential Innovation Fund
Memorial Sloan Kettering Cancer Center (MSK) announced the launch of the Fiona and Stanley Druckenmiller Presidential Innovation Fund, which is intended to lead to new, more effective ways to treat and cure cancer by rapidly seeding the most promising projects in translational cancer medicine that might otherwise go unfunded.
[Memorial Sloan Kettering Cancer Center]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-Class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.
[Fate Therapeutics, Inc.]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-Derived Allogeneic Cell Therapies
Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement to develop and commercialize up to four iPSC derived, engineered natural killer cell and / or T cell programs for hematologic malignancies and solid tumors.
[Century Therapeutics]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
CRISPR/Cas9-Mediated Gene Knockout and Interallelic Gene Conversion in Human Induced Pluripotent Stem Cells Using Non-Integrative Bacteriophage-Chimeric Retrovirus-Like Particles
Researchers investigated the potential of bacteriophage-chimeric retrovirus-like particles for the non-integrative delivery of RNA molecules in human iPSCs for CRISPR/Cas9 applications.
[BMC Biology]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Patient-Derived iPSCs Link Elevated Mitochondrial Respiratory Complex I Function to Osteosarcoma in Rothmund-Thomson Syndrome
The authors generated Rothmund-Thomson syndrome (RTS) patient-derived iPSCs to dissect the pathological signaling leading to RTS patient-associated osteosarcoma.
[PLoS Genetics]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
